In both trials, guselkumab significantly surpassed placebo for primary composite endpoints of clinical response at week 12 followed by either clinical remission or endoscopic response at week 48.
In both trials, guselkumab significantly surpassed placebo for primary composite endpoints of clinical response at week 12 followed by either clinical remission or endoscopic response at week 48.
In both trials, guselkumab...